2017
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Foss F, Horwitz S, Pro B, Miles Prince H, Sokol L, Balser B, Wolfson J, Coiffier B. Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal Of Hematology & Oncology 2017, 10: 154. PMID: 28923081, PMCID: PMC5603163, DOI: 10.1186/s13045-017-0518-8.Peer-Reviewed Original Research
2015
Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma
Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica 2015, 100: 794-800. PMID: 25795722, PMCID: PMC4450625, DOI: 10.3324/haematol.2015.123711.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaComplete remissionRecombinant immunotoxinCommon adverse eventsDose-escalation trialLow tumor burdenAssessment Tool scoreDurable remissionsEscalation trialPartial remissionAdverse eventsTumor burdenIntravenous infusionPatientsRemissionTool scoreResponse rateSingle-chain antibody fragmentChain antibody fragmentsLymphomaDiphtheria toxinFurther studiesImmunotoxinTrials
2012
Pralatrexate: treatment of T-cell non-Hodgkins lymphoma
Parker T, Barbarotta L, Foss F. Pralatrexate: treatment of T-cell non-Hodgkins lymphoma. Future Oncology 2012, 9: 21-29. PMID: 23252560, DOI: 10.2217/fon.12.168.Peer-Reviewed Original ResearchConceptsRefractory peripheral T-cell lymphomaPeripheral T-cell lymphomaT-cell non-Hodgkin lymphomaVitamin B12 supplementationOverall response rateNon-Hodgkin lymphomaT-cell lymphomaPROPEL trialCommon toxicitiesB12 supplementationPatient populationClinical studiesResponse ratePralatrexateUS FDALymphomaMetabolic inhibitorsTreatmentToxicityNauseaThrombocytopeniaDoseTrialsSupplementationWeeksLong‐term follow‐up and survival of cutaneous T‐cell lymphoma patients treated with extracorporeal photopheresis
Knobler R, Duvic M, Querfeld C, Straus D, Horwitz S, Zain J, Foss F, Kuzel T, Campbell K, Geskin L. Long‐term follow‐up and survival of cutaneous T‐cell lymphoma patients treated with extracorporeal photopheresis. Photodermatology Photoimmunology & Photomedicine 2012, 28: 250-257. PMID: 22971190, DOI: 10.1111/j.1600-0781.2012.00689.x.Peer-Reviewed Original ResearchConceptsDuration of responseOverall response rateExtracorporeal photopheresisOverall survivalSkin responseResponse rateImpact of ECPCutaneous T-cell lymphomaMedian overall survivalSurvival of patientsT-cell lymphomaLong-term treatmentECP initiationDurable responsesPivotal trialsPatientsCohortECP treatmentModern criteriaSurvivalTreatmentDiagnosisTrialsMonthsResponse
2011
Relapsed and refractory PTCL—into the therapeutic abyss
Foss F. Relapsed and refractory PTCL—into the therapeutic abyss. Nature Reviews Clinical Oncology 2011, 8: 321-322. PMID: 21468128, DOI: 10.1038/nrclinonc.2011.51.Peer-Reviewed Original Research
2003
Novel agents for cutaneous T-cell lymphoma
Kuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma. Hematology/Oncology Clinics Of North America 2003, 17: 1459-1466. PMID: 14710896, DOI: 10.1016/s0889-8588(03)00112-6.Peer-Reviewed Original Research